Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multicentre study 'Prague 19'

European Heart Journal

Volumn 35, Issue 12, 2014, Pages 787-794

  Kočka, Viktor ^a   Malý, Martin ^b   Toušek, Petr ^a   Buděšínský, Tomas ^a   Lisa, Libor ^a   Prodanov, Petko ^a   Jarkovský, Jiri ^c   Widimský, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Acute myocardial infarction; Biodegradable stent; Bioresorbable vascular scaffold; Optical coherence tomography; Primary PCI

Indexed keywords

ACETYLSALICYLIC ACID; POLYLACTIC ACID; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; BALLOON DILATATION; BARE METAL STENT; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SCAFFOLD STRUT MALAPPOSITION; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOLYSIS IN MYOCARDIAL INFARCTION FLOW SCORE; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MYOCARDIAL INFARCTION; TISSUE SCAFFOLD; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CORONARY ANGIOGRAPHY; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84896985220     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht545     Document Type: Review

References (18)

1. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362: 1663-1674.
2. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, Lowik MM, van der Palen J, Verhorst PM, de Man FH. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012; 59:1350-1361.
3. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-1402.
4. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007;69:128-131.
5. Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, Thuesen L, Mc Clean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Chevalier B, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv 2011;4:1271-1280.
6. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, Mc Clean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement:does bior-esorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013;99:98-105.
7. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, Mc Greevy R, Veldhof S. Abioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
8. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
9. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122: 2288-2300.
10. Kume T, Okura H, Miyamoto Y, Yamada R, Saito K, Tamada T, Koyama T, Neishi Y, Hayashida A, Kawamoto T, Yoshida K. Natural historyofstentedge dissection, tissue protrusion and incomplete stent apposition detectable only on optical coherence tomography after stent implantation-preliminary observation. Circ J 2012;76: 698-703.
11. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, Mc Clean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-1588.
12. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, Mc Clean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122:2301-2312.
13. Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, van Geuns RJ, Dorange C, Veldhof S, Rapoza R, Whitbourn R, Windecker S, Garcia-Garcia HM, Regar E, Serruys PW. A comparative assessment by optical coherence tomography of the performanceofthefirst and second generationofthe everolimus-eluting bior-esorbable vascular scaffolds. Eur Heart J 2011;32:294-304.
14. Gomez-Lara J, Radu M, Brugaletta S, Farooq V, Diletti R, Onuma Y, Windecker S, Thuesen L, Mc Clean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Serial analysis of the malapposed and uncovered strutsofthe newgenerationofeverolimus- eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv 2011;4:992-1001.
15. Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Onuma Y, Garcia-Garcia HM, Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design. Am Heart J 2012;164: 654-663.
16. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Garg S, Regar E, De Bruyne B, Windecker S, Mc Clean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Dorange C, Veldhof S, Morel MA, de Vries T, Ormiston JA, Serruys PW. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010;3:1190-1198.
17. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, Mc Clean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1. 0 and 1. 1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011;78:3-12.
18. Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, Gogas BD, van Geuns RJ, Regar E, Schultz C, Windecker S, Lefevre T, Brueren BR, Powers J, Perkins LL, Rapoza RJ, Virmani R, Garcia-Garcia HM, Serruys PW. Opticalcoherence tomography (OCT) ofoverlapping bioresorbable scaffolds: from benchworktoclin-ical application. Euro Intervention 2011;7:386-399.